Eli Paul Lerner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eli Paul Lerner has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- John Maringa Githaka
Department of Medical Oncology, WVU Cancer Institute, 1 Medical Center Drive, Morgantown, WV 26506, USA
3 shared publications - Eytan Wine
University of Alberta
2 shared publications Troy Perry
Division of Pediatric Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
2 shared publications- Troy Perry
University of Alberta
2 shared publications - Adam P. Silverman
Denali Therapeutics Inc., South San Francisco, California, USA
1 shared publication - Adrienn Volak
Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02114, USA
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Real‐world paediatric inflammatory bowel disease surgery: International variation in care and practice
Objective: Paediatric inflammatory bowel disease (IBD) surgery is delivered across heterogeneous settings, with limited paediatric‐specific evidence guiding organisation of care, perioperative management, and operative strategy. We characterised contemporary international practice. Methods: An international cross‐sectional centre‐level survey was conducted within the Paediatric IBD Surgery Network. A 28‐item questionnaire addressing organisation of care, perioperative management, procedural volumes, and surgical practice was distributed electronically. Analyses were descriptive and performed per question. Results: Twenty‐six of 36 invited centres from 14 countries responded (72%). University or teaching hospitals represented 96% of centres, and paediatric surgeons accounted for 69% of respondents. Regular multidisciplinary team meetings were reported by 85%. Use of an enhanced recovery after surgery protocol, structured nutritional screening, and deferral of elective surgery for nutritional optimisation whenever feasible were reported by 50%, 54%, and 42% of centres, respectively. Medication withholding varied, from corticosteroids in 69% of centres to anti‐tumour necrosis factor (anti‐TNF) agents in 31% and individual newer biologic or small‐molecule classes in 15–19%. Formal national centralisation was reported as recommended or mandatory by 42%. Median annual luminal Crohn's disease surgery volume per centre was two procedures (interquartile range [IQR] 1–5) in 2018, 2.5 (IQR 2–5) in 2022, and 2.5 (IQR 1–5) in 2024. Median annual ileal pouch–anal anastomosis volume in children with ulcerative colitis was 1 (IQR 0.1–3.5). Conclusions: Considerable variation was observed in perioperative optimisation and medication management, integration of medical and surgical therapy, centralisation, and operative strategy. These findings provide a baseline for international benchmarking, consensus development, and prospective collaborative research.
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessReal‐world paediatric inflammatory bowel disease surgery: International variation in care and practice
Objective: Paediatric inflammatory bowel disease (IBD) surgery is delivered across heterogeneous settings, with limited paediatric‐specific evidence guiding organisation of care, perioperative management, and operative strategy. We characterised contemporary international practice. Methods: An international cross‐sectional centre‐level survey was conducted within the Paediatric IBD Surgery Network. A 28‐item questionnaire addressing organisation of care, perioperative management, procedural volumes, and surgical practice was distributed electronically. Analyses were descriptive and performed per question. Results: Twenty‐six of 36 invited centres from 14 countries responded (72%). University or teaching hospitals represented 96% of centres, and paediatric surgeons accounted for 69% of respondents. Regular multidisciplinary team meetings were reported by 85%. Use of an enhanced recovery after surgery protocol, structured nutritional screening, and deferral of elective surgery for nutritional optimisation whenever feasible were reported by 50%, 54%, and 42% of centres, respectively. Medication withholding varied, from corticosteroids in 69% of centres to anti‐tumour necrosis factor (anti‐TNF) agents in 31% and individual newer biologic or small‐molecule classes in 15–19%. Formal national centralisation was reported as recommended or mandatory by 42%. Median annual luminal Crohn's disease surgery volume per centre was two procedures (interquartile range [IQR] 1–5) in 2018, 2.5 (IQR 2–5) in 2022, and 2.5 (IQR 1–5) in 2024. Median annual ileal pouch–anal anastomosis volume in children with ulcerative colitis was 1 (IQR 0.1–3.5). Conclusions: Considerable variation was observed in perioperative optimisation and medication management, integration of medical and surgical therapy, centralisation, and operative strategy. These findings provide a baseline for international benchmarking, consensus development, and prospective collaborative research.
- 21 September 2026
- Published by SAGE Publications in Biopreservation and Biobanking
From Archetypes to Access: A Two-Axis Governance Framework and Decision-Support Tool for Rare Specimen Biobanking
Introduction: Biobanks fulfill their scientific and ethical mandates when collected specimens are used effectively. Access policies govern researcher eligibility, allocation, oversight, and intellectual property (IP) considerations. Despite their importance, access policies vary substantially and lack a unifying practical framework. Objectives: We sought to identify commonalities and areas of under-specification across access policies in surgically oriented, pediatric, and/or national biobanks to describe real-world practices and develop a typology of rare biospecimen governance. Methods: We conducted a targeted scoping review of access policies from 32 biobanks identified from the Biobank Resource Centre Biobank Locator, with 19 providing sufficient governance information (59% response). Responses were coded using 10 domains researcher eligibility, oversight, allocation rules, data/sample coupling, industry access, fees, reporting, authorship, unused sample handling, and IP. Descriptive statistics and comparative analysis were used to identify patterned co-variation. A large language model (ChatGPT and OpenAI) was used to organize coded attributes and generate potential governance typologies, which were refined and verified by the authors. Results: Governance attributes clustered along two conceptually distinct dimensions Access Orientation (facilitative vs. stewardship-oriented) and Allocation Logic (procedurally neutral vs. strategically prioritized). Their interaction produced four corresponding governance archetypes: Academic Commons, Rare Specimen Stewardship, Investigator-Led Facilitation, and Protected National Strategic Asset. Unused sample handling and IP were the most frequently under-specified domains. No novel structural configurations emerged after 13 cases. Conclusion: Access policy variations reflect coherent governance orientations that reveal differing institutional priorities and conceptions of the biobank’s role in research facilitation and stewardship. By articulating two analytic axes and four archetypes, we provide a practical framework for interpreting policy differences across biobanks and identifying areas of under-specification. New and evolving biobanks can use this typology to align policies with their mission, scarcity constraints, and ethical obligations, supporting transparent decision-making and responsible and effective use of research specimens.
- 21 September 2026
- Published by SAGE Publications in Biopreservation and Biobanking
From Archetypes to Access: A Two-Axis Governance Framework and Decision-Support Tool for Rare Specimen Biobanking
Introduction: Biobanks fulfill their scientific and ethical mandates when collected specimens are used effectively. Access policies govern researcher eligibility, allocation, oversight, and intellectual property (IP) considerations. Despite their importance, access policies vary substantially and lack a unifying practical framework. Objectives: We sought to identify commonalities and areas of under-specification across access policies in surgically oriented, pediatric, and/or national biobanks to describe real-world practices and develop a typology of rare biospecimen governance. Methods: We conducted a targeted scoping review of access policies from 32 biobanks identified from the Biobank Resource Centre Biobank Locator, with 19 providing sufficient governance information (59% response). Responses were coded using 10 domains researcher eligibility, oversight, allocation rules, data/sample coupling, industry access, fees, reporting, authorship, unused sample handling, and IP. Descriptive statistics and comparative analysis were used to identify patterned co-variation. A large language model (ChatGPT and OpenAI) was used to organize coded attributes and generate potential governance typologies, which were refined and verified by the authors. Results: Governance attributes clustered along two conceptually distinct dimensions Access Orientation (facilitative vs. stewardship-oriented) and Allocation Logic (procedurally neutral vs. strategically prioritized). Their interaction produced four corresponding governance archetypes: Academic Commons, Rare Specimen Stewardship, Investigator-Led Facilitation, and Protected National Strategic Asset. Unused sample handling and IP were the most frequently under-specified domains. No novel structural configurations emerged after 13 cases. Conclusion: Access policy variations reflect coherent governance orientations that reveal differing institutional priorities and conceptions of the biobank’s role in research facilitation and stewardship. By articulating two analytic axes and four archetypes, we provide a practical framework for interpreting policy differences across biobanks and identifying areas of under-specification. New and evolving biobanks can use this typology to align policies with their mission, scarcity constraints, and ethical obligations, supporting transparent decision-making and responsible and effective use of research specimens.
- Open Access
- 1 September 2026
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 331 (3) , G328-G347
Host-microbe interactions in the appendix of children with inflammatory bowel diseases
Multiomics profiling of pediatric appendiceal tissue in inflammatory bowel diseases reveals reduced microbial diversity, Proteobacteria enrichment, and coordinated associations between microbial functional pathways and host immune-related transcripts. Invasive capacity of appendix-derived Klebsiella variicola further supports potential host-microbe interactions within this niche. These findings characterize the appendix as a distinct mucosal compartment in pediatric IBD and provide a foundation for future mechanistic investigation.
- 1 September 2026
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 331 (3) , G328-G347
Open AccessHost-microbe interactions in the appendix of children with inflammatory bowel diseases
Multiomics profiling of pediatric appendiceal tissue in inflammatory bowel diseases reveals reduced microbial diversity, Proteobacteria enrichment, and coordinated associations between microbial functional pathways and host immune-related transcripts. Invasive capacity of appendix-derived Klebsiella variicola further supports potential host-microbe interactions within this niche. These findings characterize the appendix as a distinct mucosal compartment in pediatric IBD and provide a foundation for future mechanistic investigation.
- Open Access
ClusToRa: A niche-centric framework for identifying structural recruitment and infiltration in spatial omics
Spatial omics maps cellular landscapes, yet current tools might conflate stochastic proximity with organized niches. We present ClusToRa (Cluster-to-Randomization), a framework that identifies high-density cellular territories and quantifies cell-type recruitment using a fixed-position null model. Benchmarked against graph-based neighborhood-enrichment and point-pattern statistics, ClusToRa reduced false-positive enrichment in simulations and resolved core-vs-boundary interactions. Applied to cirrhotic MASH liver, ClusToRa identifies stellate-cell territories with immune/endothelial infiltration and stress-, Notch-, and PPARα-associated programs, providing a niche-centric framework for distinguishing structural cellular infiltration from boundary adjacency or density-driven colocalization.
Open AccessClusToRa: A niche-centric framework for identifying structural recruitment and infiltration in spatial omics
Spatial omics maps cellular landscapes, yet current tools might conflate stochastic proximity with organized niches. We present ClusToRa (Cluster-to-Randomization), a framework that identifies high-density cellular territories and quantifies cell-type recruitment using a fixed-position null model. Benchmarked against graph-based neighborhood-enrichment and point-pattern statistics, ClusToRa reduced false-positive enrichment in simulations and resolved core-vs-boundary interactions. Applied to cirrhotic MASH liver, ClusToRa identifies stellate-cell territories with immune/endothelial infiltration and stress-, Notch-, and PPARα-associated programs, providing a niche-centric framework for distinguishing structural cellular infiltration from boundary adjacency or density-driven colocalization.
- 20 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (7) , 1690-1700
The Impact of Integrating Pelvic Magnetic Resonance Imaging at Diagnosis on Early Detection of Perianal Crohn's Disease in Pediatrics
INTRODUCTION: Perianal Crohn's disease (CD) can be a severe manifestation of pediatric CD. Earlier detection may alter outcomes. The aim of this study was to determine if performing pelvic magnetic resonance imaging (MRI) on newly diagnosed pediatric patients with CD would identify asymptomatic perianal CD and lead to earlier biologic use and less perianal surgery. METHODS: Patients were prospectively enrolled into the Edmonton Pediatric Inflammatory Bowel Disease Clinic registry (baseline pelvic MRI since 2018). A retrospective review (2018–2023) was performed. A blinded radiologist re-read the positive MRIs using St. James and Parks criteria. RESULTS: One hundred thirty-nine patients were included (median age 13 [interquartile range 11–16, range 6–18]). Overall, 19% (n = 27/139) had subclinical perianal disease (MR+/asymptomatic [ASx]). For patients who were both asymptomatic and had a normal perianal examination (n = 86/139, 62%), their subclinical perianal disease rate was similar at 20% (n = 17/86). Compared with MR−/ASx, MR+/ASx patients had a relative risk of 1.40 (95% confidence interval [CI] 1.18–1.68) and 1.32 (95% CI 1.17–1.52) of starting a biologic at 6 and 12 months, respectively. MR+/Sx needed the most and earliest perianal surgery, but MR+/ASx also had higher rates and faster time to perianal surgery than MR−/ASx (P = 0.02). Perianal side branch fistula was a predictor of surgery (odds ratio 107.6, [95% CI 16.9–2,178] P < 0.0001). DISCUSSION: One in 5 newly diagnosed pediatric patients with CD had subclinical perianal disease, even when having a normal perianal physical examination. These patients needed more and earlier perianal surgery and had higher biologic use despite their perianal disease being subclinical. Adding routine MR imaging at the time of pediatric CD diagnosis may help inform treatment decisions and improve these outcomes.
- 20 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (7) , 1690-1700
The Impact of Integrating Pelvic Magnetic Resonance Imaging at Diagnosis on Early Detection of Perianal Crohn's Disease in Pediatrics
INTRODUCTION: Perianal Crohn's disease (CD) can be a severe manifestation of pediatric CD. Earlier detection may alter outcomes. The aim of this study was to determine if performing pelvic magnetic resonance imaging (MRI) on newly diagnosed pediatric patients with CD would identify asymptomatic perianal CD and lead to earlier biologic use and less perianal surgery. METHODS: Patients were prospectively enrolled into the Edmonton Pediatric Inflammatory Bowel Disease Clinic registry (baseline pelvic MRI since 2018). A retrospective review (2018–2023) was performed. A blinded radiologist re-read the positive MRIs using St. James and Parks criteria. RESULTS: One hundred thirty-nine patients were included (median age 13 [interquartile range 11–16, range 6–18]). Overall, 19% (n = 27/139) had subclinical perianal disease (MR+/asymptomatic [ASx]). For patients who were both asymptomatic and had a normal perianal examination (n = 86/139, 62%), their subclinical perianal disease rate was similar at 20% (n = 17/86). Compared with MR−/ASx, MR+/ASx patients had a relative risk of 1.40 (95% confidence interval [CI] 1.18–1.68) and 1.32 (95% CI 1.17–1.52) of starting a biologic at 6 and 12 months, respectively. MR+/Sx needed the most and earliest perianal surgery, but MR+/ASx also had higher rates and faster time to perianal surgery than MR−/ASx (P = 0.02). Perianal side branch fistula was a predictor of surgery (odds ratio 107.6, [95% CI 16.9–2,178] P < 0.0001). DISCUSSION: One in 5 newly diagnosed pediatric patients with CD had subclinical perianal disease, even when having a normal perianal physical examination. These patients needed more and earlier perianal surgery and had higher biologic use despite their perianal disease being subclinical. Adding routine MR imaging at the time of pediatric CD diagnosis may help inform treatment decisions and improve these outcomes.
- 2 May 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (29) , 2530-2546
Multiple anti-tumor programs are activated by blocking BAD phosphorylation
The Bcl-2 family member BAD is a candidate disease modulator because it stimulates apoptosis in a cell context basis and inhibits cell migration during normal mammary gland morphogenesis. This activity depends on 3 key regulatory serines (S75, 99, 118) in the unphosphorylated state. Given that developmental programs are often hijacked in cancer, we hypothesized that BAD would impede breast cancer progression. We generated breast cancer mouse models representing loss-of-function or phosphorylation deficient mutations (PyMT-Bad−/− and PyMT-Bad3SA/3SA, respectively). Preventing BAD phosphorylation significantly decreased breast cancer progression and metastasis. The knock-out phenocopied the control PyMT-Bad+/+ suggesting that phosphorylated BAD protein was inert. Thus, the BAD3SA mutation unmasked latent anti-tumor activity. Indeed, transcriptomics showed PyMT-Bad3SA/3SA activated multiple anti-tumor programs including apoptosis, inflammation, cellular differentiation, and diminished cell migration. This anti-tumor effect associated with clinical survival of breast cancer patients whose tumors had high levels of unphosphorylated BAD. Kinase screens identified ERK as the major BAD kinase in breast cells, and ERK inhibition impeded tumoroid invasion. Our data suggest that unphosphorylated BAD modulates anti-tumor pathways that contribute to excellent patient prognosis. Thus, targeting ERK to dephosphorylate BAD may be an exciting therapeutic opportunity in the future.
- 2 May 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (29) , 2530-2546
Multiple anti-tumor programs are activated by blocking BAD phosphorylation
The Bcl-2 family member BAD is a candidate disease modulator because it stimulates apoptosis in a cell context basis and inhibits cell migration during normal mammary gland morphogenesis. This activity depends on 3 key regulatory serines (S75, 99, 118) in the unphosphorylated state. Given that developmental programs are often hijacked in cancer, we hypothesized that BAD would impede breast cancer progression. We generated breast cancer mouse models representing loss-of-function or phosphorylation deficient mutations (PyMT-Bad−/− and PyMT-Bad3SA/3SA, respectively). Preventing BAD phosphorylation significantly decreased breast cancer progression and metastasis. The knock-out phenocopied the control PyMT-Bad+/+ suggesting that phosphorylated BAD protein was inert. Thus, the BAD3SA mutation unmasked latent anti-tumor activity. Indeed, transcriptomics showed PyMT-Bad3SA/3SA activated multiple anti-tumor programs including apoptosis, inflammation, cellular differentiation, and diminished cell migration. This anti-tumor effect associated with clinical survival of breast cancer patients whose tumors had high levels of unphosphorylated BAD. Kinase screens identified ERK as the major BAD kinase in breast cells, and ERK inhibition impeded tumoroid invasion. Our data suggest that unphosphorylated BAD modulates anti-tumor pathways that contribute to excellent patient prognosis. Thus, targeting ERK to dephosphorylate BAD may be an exciting therapeutic opportunity in the future.
- Open Access
- 10 October 2020
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 29 (17) , 2920-2935
Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation
Neuroinflammation is a key contributor to the pathology of Alzheimer’s disease (AD). CD33 (Siglec-3) is a transmembrane sialic acid-binding receptor on the surface of microglial cells. CD33 is upregulated on microglial cells from post-mortem AD patient brains, and high levels of CD33 inhibit uptake and clearance of amyloid beta (Aβ) in microglial cell cultures. Furthermore, knockout of CD33 reduces amyloid plaque burden in mouse models of AD. Here, we tested whether a gene therapy strategy to reduce CD33 on microglia in AD could decrease Aβ plaque load. Intracerebroventricular injection of an adeno-associated virus (AAV) vector-based system encoding an artificial microRNA targeting CD33 (miRCD33) into APP/PS1 mice reduced CD33 mRNA and TBS-soluble Aβ40 and Aβ42 levels in brain extracts. Treatment of APP/PS1 mice with miRCD33 vector at an early age (2 months) was more effective at reducing Aβ plaque burden than intervening at later times (8 months). Furthermore, early intervention downregulated several microglial receptor transcripts (e.g. CD11c, CD47 and CD36) and pro-inflammatory activation genes (e.g. Tlr4 and Il1b). Marked reductions in the chemokine Ccl2 and the pro-inflammatory cytokine Tnfα were observed at the protein level in the brain of APP/PS1 mice treated with miRCD33 vector. Overall, our data indicate that CD33 is a viable target for AAV-based knockdown strategies to reduce AD pathology. One Sentence Summary: A gene therapy approach for Alzheimer’s disease using adeno-associated virus vector-based knockdown of CD33 reduced amyloid beta accumulation and neuroinflammation.
- 10 October 2020
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 29 (17) , 2920-2935
Open AccessGene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation
Neuroinflammation is a key contributor to the pathology of Alzheimer’s disease (AD). CD33 (Siglec-3) is a transmembrane sialic acid-binding receptor on the surface of microglial cells. CD33 is upregulated on microglial cells from post-mortem AD patient brains, and high levels of CD33 inhibit uptake and clearance of amyloid beta (Aβ) in microglial cell cultures. Furthermore, knockout of CD33 reduces amyloid plaque burden in mouse models of AD. Here, we tested whether a gene therapy strategy to reduce CD33 on microglia in AD could decrease Aβ plaque load. Intracerebroventricular injection of an adeno-associated virus (AAV) vector-based system encoding an artificial microRNA targeting CD33 (miRCD33) into APP/PS1 mice reduced CD33 mRNA and TBS-soluble Aβ40 and Aβ42 levels in brain extracts. Treatment of APP/PS1 mice with miRCD33 vector at an early age (2 months) was more effective at reducing Aβ plaque burden than intervening at later times (8 months). Furthermore, early intervention downregulated several microglial receptor transcripts (e.g. CD11c, CD47 and CD36) and pro-inflammatory activation genes (e.g. Tlr4 and Il1b). Marked reductions in the chemokine Ccl2 and the pro-inflammatory cytokine Tnfα were observed at the protein level in the brain of APP/PS1 mice treated with miRCD33 vector. Overall, our data indicate that CD33 is a viable target for AAV-based knockdown strategies to reduce AD pathology. One Sentence Summary: A gene therapy approach for Alzheimer’s disease using adeno-associated virus vector-based knockdown of CD33 reduced amyloid beta accumulation and neuroinflammation.
- 30 March 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (5) , 2144-2155
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
The apolipoprotein E E4 allele of the APOE gene is the strongest genetic factor for late-onset Alzheimer disease (LOAD). There is compelling evidence that apoE influences Alzheimer disease (AD) in large part by affecting amyloid β (Aβ) aggregation and clearance; however, the molecular mechanism underlying these findings remains largely unknown. Herein, we tested whether anti–human apoE antibodies can decrease Aβ pathology in mice producing both human Aβ and apoE4, and investigated the mechanism underlying these effects. We utilized APPPS1-21 mice crossed to apoE4-knockin mice expressing human apoE4 (APPPS1-21/APOE4). We discovered an anti–human apoE antibody, anti–human apoE 4 (HAE-4), that specifically recognizes human apoE4 and apoE3 and preferentially binds nonlipidated, aggregated apoE over the lipidated apoE found in circulation. HAE-4 also binds to apoE in amyloid plaques in unfixed brain sections and in living APPPS1-21/APOE4 mice. When delivered centrally or by peripheral injection, HAE-4 reduced Aβ deposition in APPPS1-21/APOE4 mice. Using adeno-associated virus to express 2 different full-length anti–apoE antibodies in the brain, we found that HAE antibodies decreased amyloid accumulation, which was dependent on Fcγ receptor function. These data support the hypothesis that a primary mechanism for apoE-mediated plaque formation may be a result of apoE aggregation, as preferentially targeting apoE aggregates with therapeutic antibodies reduces Aβ pathology and may represent a selective approach to treat AD.
- 30 March 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (5) , 2144-2155
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
The apolipoprotein E E4 allele of the APOE gene is the strongest genetic factor for late-onset Alzheimer disease (LOAD). There is compelling evidence that apoE influences Alzheimer disease (AD) in large part by affecting amyloid β (Aβ) aggregation and clearance; however, the molecular mechanism underlying these findings remains largely unknown. Herein, we tested whether anti–human apoE antibodies can decrease Aβ pathology in mice producing both human Aβ and apoE4, and investigated the mechanism underlying these effects. We utilized APPPS1-21 mice crossed to apoE4-knockin mice expressing human apoE4 (APPPS1-21/APOE4). We discovered an anti–human apoE antibody, anti–human apoE 4 (HAE-4), that specifically recognizes human apoE4 and apoE3 and preferentially binds nonlipidated, aggregated apoE over the lipidated apoE found in circulation. HAE-4 also binds to apoE in amyloid plaques in unfixed brain sections and in living APPPS1-21/APOE4 mice. When delivered centrally or by peripheral injection, HAE-4 reduced Aβ deposition in APPPS1-21/APOE4 mice. Using adeno-associated virus to express 2 different full-length anti–apoE antibodies in the brain, we found that HAE antibodies decreased amyloid accumulation, which was dependent on Fcγ receptor function. These data support the hypothesis that a primary mechanism for apoE-mediated plaque formation may be a result of apoE aggregation, as preferentially targeting apoE aggregates with therapeutic antibodies reduces Aβ pathology and may represent a selective approach to treat AD.